Home
Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.61
Change (%) Stock is Up 0.01 (1.67%)
Volume300
Data as of 05/24/13 3:43 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
May 15, 2013
Tengion Provides Business Update and Reports First Quarter 2013 Financial Results
-- Phase 1 trial of Neo-Kidney Augment™ on track for initiation in Sweden in second quarter of 2013 and in U.S. in fourth quarter of 2013 -- -- Actively recruiting for final three patients in Neo-Urinary Conduit™ trial -- WINSTON-SALEM, N.C., May 15, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the first quarter ended March 31, 2013. "We are very pleased to have achieved a sig... 
April 01, 2013
Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
WINSTON-SALEM, N.C., April 1, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the acceptance of the Company's Clinical Trial Application (CTA) filed with the Medical Products Agency (MPA) in Sweden to initiate a Phase 1 clinical trial to evaluate the safety and delivery of its Neo-Kidney Augment™ product in up to five patients with advanced chronic kidney disease (CKD).  "We are excited to have received MPA approval for the Neo-Kidney Augm...